Press Release

AB-Therapeutics new anticancer compounds reduce by 70% lung tumors growth

The Barcelona based biotech company is in a series-A fundraising round to conduct preclinical development and to file an IND in late 2011

November 8, 2010

The Barcelona-based biotech company AB Therapeutics has obtained high efficacy results with its 2 new anticancer compounds in animal models of lung cancer (NSCLC) using Membrane Lipid Therapy (MLT), a new therapeutic approach. After 4 weeks treatment in immunosupressed mice, the molecules reduced tumor growth in treated animals by 70%. Additionally, tumor growth arrest was observed in 10% of treated mice. Adverse events were markedly lower than in mice treated with gold standard treatment docetaxel.
AB-Therapeutics is in a series-A fundraising round to conduct preclinical development and to file an IND in 3Q2011 to start phase I clinical trials in late 2011. Capital needs are 0.8-1 M€ in 2010, 2.8 M€ in 2011 and 5 M€ in 2012. The company expects to receive 2 M€ in government soft loans from European, Spanish and Catalan institutions.
 
“We are satisfied to have in vivo validation of in vitro results, not only in efficacy but also in low toxicity”, said Jordi Espadaler, PhD, VP Discovery Research. “The results obtained will allow us to build the regulatory preclinical package to start clinical trials next year. We have initiated a series A round of financing to accomplish this goal”, said Carles Domenech, PhD, CEO.
 
Dr. Domenech highlights that MLT “could represent an important contribution to human health”, and also points at its high market potential: “Our compounds have blockbuster potential due to the high mortality in lung cancer, still an unmet medical need”.
 
ABOUT MEMBRANE LIPID THERAPY
MLT is a new therapeutic approach, with a mechanism of action consisting in modifying the dynamics of cell membranes, thus altering the activity of multiple proteins involved in cell growth regulation.
 
Molecules under preclinical development selectively induce apoptosis in several cancer types: lung, pancreatic, glioma and leukemia.
 
ABOUT AB-THERAPEUTICS
 
AB-Therapeutics, SL is a drug discovery and development company headquartered in Barcelona, Catalonia, Spain, with planned US facilities in Boston. The company was cofounded in late 2009 by AB Biotics, SA, a company publicly traded at the Spanish alternative stock market (MAB), Carles Domenech (CEO) and Jordi Espadaler (VP Discovery Research).
 
AB-Therapeutics, SL develops safer human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. It has a molecule ready to start preclinical development in 4Q2010, with Phase I clinical trials (first in man) starting in late 2011 / early 2012. A second drug candidate will start preclinical development in 2Q2011.
 
 
Contact:
Media relations:
Nuria Peláez
Tel. +34 902 903 844
media.relations@ab-therapeutics.com
 
Investors:
Carles Domènech, PhD
Tel. +34 935 868 977
contact@ab-therapeutics.com

LATEST NEWS

11.03.2024

Press Release

AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023

Press Release

Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022

Press Release

AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022

Press Release

AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022

Press Release

AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
02.11.2022

Press Release

ABTL0812 shows potential against glioblastoma brain tumors + info
07.10.2022

Press Release

AbilityPharma Secures 2,2M € of Non-Dilutive Funding from the Ministry of Science & Innovation of the Government of Spain to Accelerate the Clinical Development and Regulatory Path of ABTL0812 + info
07.09.2022

Press Release

Carles Domènech, Executive Chairman & CEO of AbilityPharma, Will Attend ESMO Congress in Paris for a Meeting with some of the most Relevant Key Opinion Leaders (KOLs) in the Treatment of Pancreatic Cancer + info
29.06.2022

Press Release

AbilityPharma Will Attend ESMO World Congress on Gastrointestinal Cancer 2022 in Barcelona + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG